Opinion: The biotech industry needs to make its case for bold change to the White House
Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and tax rules, writes former Trump administration official Joe Grogan.
On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new frenzy among lobbyists and consultants. That frenzy has gone into overdrive with the latest proposal from the White House to examine cuts to Medicaid drug reimbursement, slashing prices to extortionate levels foreign governments demand.
Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in Trump’s vision for a new American Golden Age?
